Telomerase Reverse Transcriptase Splice Research Articles

Physiological and pathological significance of human telomerase reverse transcriptase splice variants

Human telomerase reverse transcriptase (hTERT) is tightly regulated at various transcriptional and post-transcriptional levels. Alternative splicing of hTERT has been shown in many human tissues and cell lines regardless of telomerase status and may play a role in regulation of telomerase activity and other cellular functions. Catalytically inactive splice variants make up a substantial proportion of total hTERT mRNA and are at least partly translated into protein. Shifts in splicing patterns occur in development, tumorigenesis and in response to exogenous stimuli in a tissue- and cell type-specific manner. This review focuses on prevalence, patterns and regulation of hTERT alternative splicing, describes associations with telomerase activity and telomere length, and discusses the potential significance of hTERT alternative splice variants in cancer as well as possible telomere-independent functions.

Human normal T lymphocytes and lymphoid cell lines do express alternative splicing variants of human telomerase reverse transcriptase (hTERT) mRNA

Alternative splicing of telomerase reverse transcriptase (hTERT) mRNA is known to contribute to regulation of telomerase activity in normal and cancerous cells, however, previous studies indicated that normal human T and B cells exhibited constitutive expression of full-length hTERT mRNA without splicing variants and that activation of telomerase upon stimulation of the cells was due to the shuttling of hTERT protein from cytoplasm to nucleus [Proc. Natl. Acad. Sci. USA 96 (1999) 5147; J. Immunol. 166 (2001) 4826]. We found that typical variants of hTERT mRNA were widespread in human lymphocyte-derived cell lines and normal stimulated T cells. In activated T cells, induction of the full-length hTERT mRNA was coupled with increased hTERT protein expression and telomerase activity. Collectively, human normal and malignant lymphocytes, like other human cells, express splicing variants of hTERT mRNA and require transcriptional activation of the hTERT gene to acquire telomerase activity.

Expression of human telomerase reverse transcriptase splice variants is well correlated with low telomerase activity in osteosarcoma cell lines

The human telomerase reverse transcriptase (hTERT) gene is a catalytic subunit of telomerase that plays an important role in maintaining telomere length. Recently, post-transcriptional (alternative splicing) and epigenetic (promoter methylation) mechanisms affecting expression of the hTERT gene have been reported as negative regulators of telomerase activity (TA). To elucidate the significance of the telomere maintenance mechanism (TMM) in osteosarcoma (OS), we examined hTERT mRNA/protein expression and methylation status in 16 OS cell lines and compared them with TA. Five (31%) of 16 OS cell lines expressed both full-length and splice variants of hTERT mRNA/protein, and 3 (19%) exhibited only full-length hTERT mRNA/protein. No hTERT mRNA/protein expression was observed in 8 cell lines (50%). TA in OS cell lines exhibiting full-length hTERT mRNA/protein without any splice variants was higher than in cell lines expressing splice variants. The promoters of the 16 OS cell lines were relatively hypermethylated, but no inverse relationship between frequency of methyl-CpG sites and hTERT expression was observed. Treatment with a demethylating agent induced hTERT mRNA/protein in only one cell line. These results suggest that the epigenetic mechanism might contribute to the regulation of the hTERT gene in a small subset of OSs, and that alternative splicing might be involved in controlling the TA of OS cell lines, thereby contributing to their TMM.

Oligomer-mediated modulation of hTERT alternative splicing induces telomerase inhibition and cell growth decline in human prostate cancer cells.

The expression of telomerase in human cells is strictly controlled by multiple mechanisms including transcription and alternative splicing of telomerase reverse transcriptase (hTERT). In this study, we demonstrated the possibility of modulating the hTERT splicing pattern in DU145 human prostate carcinoma cells through the use of 2'-O-methyl-RNA phosphorothioate oligonucleotides targeting the splicing site located between intron 5 and exon 6 in the hTERT pre-mRNA. An 18-h oligonucleotide exposure induced a decrease in the full-length hTERT transcript and a concomitant increase in the alternatively spliced transcripts, which resulted in significant inhibition of telomerase catalytic activity. Moreover, exposure to the R7 oligomer (which induced the most pronounced modulation of the hTERT splicing pattern and the greatest telomerase inhibition) caused a marked reduction in DU145 cell growth and the induction of apoptosis starting 2 days after treatment. Such data support the concept that down-regulation of hTERT expression can cause short-term effects on tumour cell growth, which are telomere-shortening independent.

Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activity.

Telomerase activity was determined in 15 breast cancers, 24 benign breast lesions, and 36 breast tissues adjacent to benign or malignant tumours. A positive TRAP (telomeric repeat amplification protocol) signal was detected in 67% of carcinomas and 29% of benign tumours. In five of ten cases, non-invaded breast tissues adjacent to telomerase-positive carcinomas also displayed telomerase activity. Conversely, in peritumoural specimens adjacent to benign lesions, telomerase activity was never detected. To investigate the regulatory mechanisms of telomerase activity in breast tissues, the expression of telomerase subunits was assessed, as well as the presence of alternatively spliced variants of human telomerase reverse transcriptase (hTERT). The presence of the hTERT full-length transcript appeared necessary for telomerase activity in breast carcinomas. Specifically, all telomerase-positive carcinomas expressed the hTERT full-length message, together with different combinations of alternatively spliced variants, whereas in telomerase-negative cancers, the hTERT full-length transcript was not detectable, or its abundance was markedly lower than that of alternatively spliced variants. Results obtained in benign tumours and normal tissues surrounding carcinomas instead showed that the presence of hTERT full-length transcript was not sufficient to determine telomerase activity. These findings suggest that in non-neoplastic tissues there are other mechanisms that suppress telomerase activity downstream from hTERT transcription and mRNA splicing and that such mechanisms have been lost during neoplastic transformation.

Possible Regulation of Telomerase Activity by Transcription and Alternative Splicing of Telomerase Reverse Transcriptase in Human Melanoma

To investigate the regulatory mechanisms of telomerase activity in human melanoma cells, we assessed the enzyme's catalytic activity and the expression of the telomerase subunits, the human telomerase RNA, the human telomerase-associated protein, and the human telomerase reverse transcriptase, in 52 melanoma lesions. Eight normal skin specimens were also studied. Telomerase activity was detected in 84.6% of melanomas, whereas all skin specimens were telomerase negative. Human telomerase-associated protein mRNA and human telomerase RNA were constitutively expressed in all melanoma and skin specimens. Although at a variable level of expression, human telomerase reverse transcriptase mRNA was detected in all but one melanomas, whereas it was never present in skin samples. Reverse transcriptase-polymerase chain reaction experiments were performed using primers within the reverse transcriptase domain of human telomerase reverse transcriptase and revealed the presence of multiple alternatively spliced transcripts in melanoma specimens. Among the 44 telomerase-positive melanomas, one showed the full-length transcript alone whereas in all other specimens a full-length message was present with different combinations of alternatively spliced variants. In these tumors the expression of the full-length transcript was generally equal to or higher than that of the alternatively spliced variants. The ratio full-length transcript to alternatively spliced species ranged from 0.6 to 5.26, with a median value of 1.18. Among the seven telomerase-negative melanomas, one displayed the beta deletion transcript alone, whereas in the remaining six tumors weak expression of the full-length transcript and a more abundant level of alternatively spliced transcripts were found. In these cases human telomerase reverse transcriptase ratio ranged from 0.09 to 1.1, with a median value of 0.40. The results suggest that transcription and alternative splicing of human telomerase reverse transcriptase are regulatory mechanisms controlling telomerase activity in melanoma.